CTI BioPharma Corp. (CTIC) stock is nearly perfect except the valuation

CTI BioPharma Corp. (NASDAQ: CTIC) closed the day trading at 5.70 down -2.23% from the previous closing price of $5.83. In other words, the price has decreased by $-0.13 from its previous closing price. On the day, 3996939 shares were traded. CTIC reached its highest trading level at $5.85 during the session, while it also had its lowest trading level at $5.48.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .



For a better understanding of CTIC, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.60 and its Current Ratio is at 3.60.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on September 01, 2022, initiated with a Buy rating and assigned the stock a target price of $13.

On July 07, 2022, Cowen started tracking the stock assigning a Outperform rating and target price of $10.

On August 09, 2021, BTIG Research started tracking the stock assigning a Buy rating and target price of $7.BTIG Research initiated its Buy rating on August 09, 2021, with a $7 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 12 when Craig Adam R sold 242,300 shares for $6.43 per share. The transaction valued at 1,557,989 led to the insider holds 27,861 shares of the business.

Craig Adam R bought 5,000 shares of CTIC for $27,500 on Aug 16. The President and CEO now owns 27,861 shares after completing the transaction at $5.50 per share. On Aug 09, another insider, BVF PARTNERS L P/IL, who serves as the Director of the company, sold 1,289,434 shares for $6.12 each. As a result, the insider received 7,891,336 and left with 6,148 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 47.41.

Stock Price History:

Over the past 52 weeks, CTIC has reached a high of $7.80, while it has fallen to a 52-week low of $1.43. The 50-Day Moving Average of the stock is 6.30, while the 200-Day Moving Average is calculated to be 4.47.

Shares Statistics:

Over the past 3-months, CTIC traded about 4.94M shares per day on average, while over the past 10 days, CTIC traded about 4.17M shares per day. A total of 114.39M shares are outstanding, with a floating share count of 114.17M. Insiders hold about 0.20% of the company’s shares, while institutions hold 80.00% stake in the company. Shares short for CTIC as of Jul 14, 2022 were 15.61M with a Short Ratio of 3.19, compared to 14.92M on Jun 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 14.33% and a Short% of Float of 15.64%.

Earnings Estimates

Current recommendations for the stock of the company come from 7 analysts. On average, analysts expect EPS of $-0.2 for the current quarter, with a high estimate of $-0.17 and a low estimate of $-0.25, while EPS last year was $-0.21. The consensus estimate for the next quarter is $-0.16, with high estimates of $-0.12 and low estimates of $-0.21.

Analysts are recommending an EPS of between $-0.74 and $-0.97 for the fiscal current year, implying an average EPS of $-0.83. EPS for the following year is $0, with 7 analysts recommending between $0.99 and $-0.6.

Revenue Estimates

Based on 7 analysts’ estimates, the company’s revenue will be $163.73M in the next fiscal year. The high estimate is $313.9M and the low estimate is $65.41M. The average revenue growth estimate for next year is up 215.50% from the average revenue estimate for this year.